Lessons From Drug Discovery for Cryoprotective Agent Design: An AI-Oriented Perspective

Area of Science:

• Biotechnology
• Cryobiology
• Biomedical Engineering

Background:

• Cryopreservation is crucial for biobanking, reproductive medicine, and transplantation.
• Current cryoprotective agents (CPAs) face limitations, including toxicity at high concentrations needed for vitrification.
• Advancements in preserving sensitive cells, organs, and organisms necessitate improved CPAs.

Purpose of the Study:

• To apply principles from drug discovery to the design of next-generation cryoprotective agents.
• To address the need for CPAs with improved safety and efficacy profiles.
• To frame cryoprotectant development as a multiparameter optimization challenge.

Main Methods:

• Drawing parallels between drug lead optimization and cryoprotectant development.
• Applying multiparameter optimization strategies to CPA design.
• Analyzing the requirements for ideal cryoprotectants.

Main Results:

• The study proposes a novel framework for CPA development inspired by drug discovery.
• It highlights the necessity of balancing multiple criteria for effective cryoprotectants.
• It suggests that a systematic, multiparameter approach can lead to improved CPAs.

Conclusions:

• Treating cryoprotectant development as a multiparameter optimization challenge, akin to drug lead optimization, is a promising strategy.
• This approach can facilitate the systematic design of safer and more effective CPAs.
• This perspective is vital for advancing cryopreservation technologies for complex biological materials.